Advertisement

Pain and Multiple Sclerosis: Pathophysiology and Treatment

  • Claudio SolaroEmail author
  • Erika Trabucco
  • Michele Messmer Uccelli
Demyelinating Disorders (DN Bourdette and V Yadav, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Demyelinating Disorders

Abstract

Pain is a common symptom in multiple sclerosis (MS) and has recently been estimated to be experienced by up to 75 % of patients. Pain can be present at any point in the course of the disease and patients may experience pain from various causes simultaneously. Pain in MS can also be secondary to other symptoms, such as spasticity, fatigue, and mood disorder. Of all drug use to treat MS symptoms, treatment for pain accounts for nearly 30 % of total use. At the same time, patients report low satisfaction with pain management. Pain affects quality of life and can influence a person’s participation in family life and work and affect mood. Most of the pain literature in the field of MS is based on open-label studies involving small numbers of subjects. Placebo-controlled trials in severe pain syndromes such as trigeminal neuralgia are unethical but for other types of MS-related pain conditions, placebo-controlled trials are ethical and necessary to establish efficacy, particularly given the well-documented placebo effect for various painful conditions This review discusses available data and emphasizes areas of pain research that require further attention

Keywords

Antiepileptic drugs Baclofen Cannabinoids Carbamazepine Central pain Gabapentin Lamotrigine Levetiracetam Multiple sclerosis Neuropathic pain treatment Opioid analgesics Painful tonic spasms Pain treatment Pregabalin Topiramate Tricyclic antidepressants Trigeminal neuralgia treatment 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Paty DW, Ebers GC. Multiple sclerosis 135–191. Philadelphia: F.A. Davis Company; 1999. p. 135–91.Google Scholar
  2. 2.
    Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C. Symptomatic medication use in multiple sclerosis. Mult Scler. 2003;9(5):458–60.PubMedCrossRefGoogle Scholar
  3. 3.
    "Part III: pain terms, a current list with definitions and notes on usage" (pp 209–214) Classification of chronic pain, second edition, IASP Task Force on Taxonomy, edited by H. Merskey and N. Bogduk, IASP Press, Seattle; 1994. p. 209–14.Google Scholar
  4. 4.
    Treede RD, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–5.PubMedCrossRefGoogle Scholar
  5. 5.
    O’Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137:96–111.PubMedCrossRefGoogle Scholar
  6. 6.
    Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol. 1984;41:1270–2.PubMedCrossRefGoogle Scholar
  7. 7.
    Vermote R, Ketalaer P, Carltonn H. Pain in multiple sclerosis patients: a prospective study using the McGill pain questionnaire. Clin Neurol Neurosurg. 1986;88:87–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Kassirer MR, Osterberg DH. Pain in chronic multiple sclerosis. J Pain Symptom Manage. 1987;2:95–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38:1830–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Stenager E, Knutsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand. 1991;84:197–200.PubMedCrossRefGoogle Scholar
  11. 11.
    Warnell P. The pain experience of a multiple sclerosis population: a descriptive study. Axon. 1991;13:26–8.PubMedGoogle Scholar
  12. 12.
    Archibald CJ, et al. Pain prevalence, severity and impact in a clinical sample of multiple sclerosis patients. Pain. 1994;58:89–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Indaco A, Iachetta C, Nappi C, Socci L, Carrieri PB. Chronic and acute pain syndromes in patients with multiple sclerosis. Acta Neurol. 1994;16:97–102.Google Scholar
  14. 14.
    Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Ital J Neurol Sci. 1995;16:629–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Beiske AG, Pedersen ED, Czujko B, Myhr KM. Pain and sensory complaints in multiple sclerosis. Eur J Neurol. 2004;1:479–82.CrossRefGoogle Scholar
  16. 16.
    Ehde DM, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler. 2003;6:605–11.CrossRefGoogle Scholar
  17. 17.
    Svendsen KB, et al. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol. 2003;60:1089–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Solaro C, et al. The prevalence of pain in multiple sclerosis. A multicenter cross-sectional study. Neurology. 2004;63:919–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Österberg A, Boivie J, Thomas KA. Central pain in multiple sclerosis-prevalence and clinical characteristics. Eur J Pain. 2005;9:531–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Ehde DM, Osborne TL, Hanley MA, Jensen MP, Kraft GH. The scope and nature of pain in persons with multiple sclerosis. Mult Scler. 2006;12:629–38.PubMedCrossRefGoogle Scholar
  21. 21.
    Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007;127:35–41.PubMedCrossRefGoogle Scholar
  22. 22.
    Piwko C, et al. Pain due to multiple sclerosis: analysis of the prevalence and economic burden in Canada. Pain Res Manag. 2007;12:259–65.PubMedGoogle Scholar
  23. 23.
    Khan F, Pallant J. Chronic pain in multiple sclerosis: prevalence, characteristics and impact on quality of life in an Australian community cohort. J Pain. 2007;8:614–23.PubMedGoogle Scholar
  24. 24.
    Boneschi M, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008;14:514–21.CrossRefGoogle Scholar
  25. 25.
    Douglas C, Wollin J, Windsor C. Illness and demographic correlates of chronic pain among a community-based sample of people with multiple sclerosis. Arch Phys Med Rehabil. 2008;89:1923–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Hirsh AT, Turner AP, Ehde DM, Haselkorn JK. Prevalence and impact of pain in multiple sclerosis: physical and psychological contributors. Arch Phys Med Rehabil. 2009;90:646–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Seixa D, Vasco Galhardo MJ, Guimarães J, Lima L. Pain in Portuguese patients with multiple sclerosis. Front Neurol. 2011;2:20.Google Scholar
  28. 28.
    Aicher SA, Silverman MB, Winkler CW, Bebo Jr BF. Hyperalgesia in an animal model of multiple sclerosis. Pain. 2004;110:560–70.PubMedCrossRefGoogle Scholar
  29. 29.
    • Olechowski CJ, Truong JJ, Kerr BJ. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain. 2009;141(1–2):156–64. This article reports the dysregulation of glutamate transport function in abnormal pain behavior in response to persistent noxious stimulation in EAE mice.PubMedCrossRefGoogle Scholar
  30. 30.
    • Thibault K, Calvino B, Pezet S. Characterisation of sensory abnormalities observed in an animal model of multiple sclerosis: a behavioural and pharmacological study. Eur J Pain. 2011;15(3):231.e1–231.e16. This article reports the clinical signs linked to pain in two models of EAE related to time-course changes in disease representing a model of sensory abnormalities in MS. Thibault et al. also reported pain relief with medications such as gabapentin, duloxetine, and tramadol.CrossRefGoogle Scholar
  31. 31.
    Waxman SG. Acquired channelopathies in nerve injury and MS. Neurology. 2001;56(12):1621–7. 26.PubMedCrossRefGoogle Scholar
  32. 32.
    Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci USA. 1999;96(14):7635–9. 6.PubMedCrossRefGoogle Scholar
  33. 33.
    • Svendsen KB, Sørensen L, Jensen TS, Hansen HJ, Bach FW. MRI of the central nervous system in MS patients with and without pain. Eur J Pain. 2011;15(4):395–401. This study compares 13 subjects with MS with chronic pain and ten patients without pain. There was no association between chronic pain and the site of demyelinating lesions.PubMedCrossRefGoogle Scholar
  34. 34.
    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Syst Rev. 2007; Issue 4. Art. No.: CD005454 doi: 10.1002/14651858.CD005454.pub2.
  35. 35.
    Solaro C, Brichetto G, Battaglia MA, Messmer Uccelli M, Mancardi GL. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci. 2005;25:307–10.PubMedCrossRefGoogle Scholar
  36. 36.
    Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia: use and side effects. Arch Neurol. 2001;19:129–36.CrossRefGoogle Scholar
  37. 37.
    Shirzadi M, Alvestad S, Hovdal H, et al. Comparison of carbamazepine rash in multiple sclerosis and epilepsy. Acta Neurol Scand. 2012;125(1):60–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Cianchetti C, Zuddas A, Randazzo AP, Perra L, Marrosu MG. Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations. Neurology. 1999;53:433.PubMedCrossRefGoogle Scholar
  39. 39.
    Breuer B, et al. Randomized double-blind, placebo-controlled two period crossover pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007;29:2022–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler. 1997;3:250–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Rossi S, et al. Effects of Levetiracetam on chronic pain in multiple sclerosis: results of a randomized placebo-controlled study. Eur J Neurol. 2009;16:360–6.PubMedCrossRefGoogle Scholar
  42. 42.
    • Falah M, Madsen C, Holbech JV, Sindrup SH. A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. Eur J Pain. 2011;15322149. This study is a randomized, double-blind, placebo-controlled, cross-over trial with levetiracetam 3,000 mg/day versus placebo. There were no differences in the ratings of pain relief but an effect in patients with lancinating pain or without touch-evoked pain was observed.Google Scholar
  43. 43.
    Solaro C, Boemker M, Tanganelli P. Pregabalin for treating paroxysmal symptoms in multiple sclerosis: a pilot study. J Neurol. 2009;256:1773–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Solaro C, Tanganelli P. Acute delirium in patients with multiple sclerosis treated with pregabalin. Clin Neuropharmacol. 2009;32:236–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Herman RM, D’Luzansky SC, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. Clin J Pain. 1992;8:338–45.PubMedCrossRefGoogle Scholar
  46. 46.
    Sadiq S, Poopatana C. Intrathecal basclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol. 2007;254:1464–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Kalman S, Österbergn A, Sörensenn J, Boivie J, Bertler A. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain. 2002;6:69–80.PubMedCrossRefGoogle Scholar
  48. 48.
    Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253.PubMedCrossRefGoogle Scholar
  49. 49.
    Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29:2068–79.PubMedCrossRefGoogle Scholar
  50. 50.
    Zajicek J, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517–26.PubMedCrossRefGoogle Scholar
  51. 51.
    Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434–41.PubMedCrossRefGoogle Scholar
  52. 52.
    Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology. 1995;45:1294–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124:2347–60.PubMedCrossRefGoogle Scholar
  54. 54.
    • Mills RJ, Young CA, Smith ET. Central trigeminal involvement in multiple sclerosis using high-resolution MRI at 3T. Br J Radiol. 2010;83:493–8. The objective of this study was to determine the prevalence of trigeminal lesions using high-resolution MRI at 3T. Forty-seven patients with MS with a high prevalence of detectable trigeminal abnormalities were studied. MRI results did not correspond to trigeminal symptoms.PubMedCrossRefGoogle Scholar
  55. 55.
    •• Cruccu G, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009;143:186–91. MRI scans were performed on 130 patients with MS: 50 with trigeminal neuralgia, 30 with trigeminal sensory disturbances other than trigeminal neuralgia and 50 without pain. Cruccu et al. concluded that the most likely cause of MS-related trigeminal neuralgia is a pontine plaque damaging the primary afferents. Nevertheless, in some patients a neurovascular contact may act as a concurring mechanism.PubMedCrossRefGoogle Scholar
  56. 56.
    Hutchins LG, Harnsberger HR, Jacobs JM, Apfelbaum RI. Trigeminal neuralgia (tic douloureux): MR imaging assessment. Radiology. 1990;175:837–41.PubMedGoogle Scholar
  57. 57.
    Lazar ML, Kirkpatrick JB. Trigeminal neuralgia and multiple sclerosis: demonstration of the plaque in an operative case. Neurosurgery. 1979;5:711–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Da Silva CJ, Da Rocha AJ, Mendes MF, Maja Jr ACM, Braga FT, Tilbery CP. Trigeminal involvement in multiple sclerosis: magnetic resonance imaging findings with clinical correlation in a series of patients. Mult Scler. 2005;11:282–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Nakashima I, Fujihara K, Kimpara T, Okita N, Takase S, Itoyama Y. Linear pontine trigeminal root lesions in multiple sclerosis: clinical and magnetic resonance imaging studies in 5 cases. Arch Neurol. 2001;58:101–4.PubMedCrossRefGoogle Scholar
  60. 60.
    Gass A, Kitchen N, MacManus DG, Moseley IF, Hennerici MG, Miller DH. Trigeminal neuralgia in patients with multiple sclerosis: lesion localization with magnetic resonance imaging. Neurology. 1997;49(4):1142–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Meaney JFM, Watt JMG, Eldridge PR, Whitehouse GH, Wells JCD, Miles JB. Association between trigeminal neuralgia and multiple sclerosis: role of magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 1995;59:253–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Broggi G, Ferroli P, Franzini A, Nazzi V, Farina L, La Mantia L, Milanese C. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55(4):830–8. discussion 838–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Cruccu G, Leandri M, Feliciani M, Manfredi M. Idiopathic and symptomatic trigeminal pain. J Neurol Neurosurg Psychiatry. 1990;53(12):1034–42.PubMedCrossRefGoogle Scholar
  64. 64.
    Bergamaschi R, Romani A, Versino M, Callieco R, Gaspari D, Citterio A, Cosi V. Usefulness of trigeminal somatosensory evoked potentials to detect subclinical trigeminal impairment in multiple sclerosis patients. Acta Neurol Scand. 1994;89:412–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ. 2000;320:1113.PubMedCrossRefGoogle Scholar
  66. 66.
    Leandri M, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol. 2000;247:556–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Solaro C, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology. 1998;51:609–11.PubMedCrossRefGoogle Scholar
  68. 68.
    Solaro C, Uccelli MM, Brichetto G, Gasperini C, Mancardi GL. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage. 2001;21:367–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Solaro C, Uccelli MM, Uccelli A, Leandri M, Mancardi GL. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 2000;44:45–8.PubMedCrossRefGoogle Scholar
  70. 70.
    DMKG Study Group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol. 2003;250(542–545).Google Scholar
  71. 71.
    Lunardi G, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology. 1997;48:1714–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology. 1998;51:611–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Zvartau-Hind M, Din MU, Gilan A, Lisak RP, Khan OA. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 2000;55:1587–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Reder AT, Arnason B. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995;45:1097–100.PubMedCrossRefGoogle Scholar
  75. 75.
    Linderoth B, Hakanson S. Paroxysmal facial pain in disseminated sclerosis treated by retrogasserian glycerol injection. Acta Neurol Scand. 1989;80:341–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Kondziolka D, Lunsford LD, Bissonette DJ. Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia. Can J Neurol Sci. 1994;21:137–40.PubMedGoogle Scholar
  77. 77.
    Berk C, Constantoyannis C, Honey CR. The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy. Can J Neurol Sci. 2003;30:220–3.PubMedGoogle Scholar
  78. 78.
    Broggi G, Franzini A. Radiofrequency trigeminal rhizotomy in treatment of symptomatic non-neoplastic facial pain. J Neurosurg. 1982;57:483–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Rogers CL, et al. Gamma knife radiosurgery for trigeminal neuralgia associated with multiple sclerosis. J Neurosurg. 2002;97 Suppl 5:529–32.PubMedGoogle Scholar
  80. 80.
    Huang E, et al. Gamma knife radiosurgery for treatment of trigeminal neuralgia in multiple sclerosis patients. Stereotact Funct Neurosurg. 2002;79:44–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Broggi G, et al. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet. 1999;354:1878–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Al-Araji AH, Oger J. Reappraisal of Lhermitte’s sign in multiple sclerosis. Mult Scler. 2005;11:398–402.PubMedCrossRefGoogle Scholar
  83. 83.
    Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. Neurology. 2000;54:1368–70.PubMedCrossRefGoogle Scholar
  84. 84.
    Solaro C, Uccelli MM, Guglieri P, Uccelli A, Mancardi GL. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler. 2000;6:192–3.PubMedGoogle Scholar
  85. 85.
    Solaro C, Tanganelli P. Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry. 2004;75:341.PubMedGoogle Scholar
  86. 86.
    Restivo DA, Tinazzi M, Patti F, Palmeri A, Maimone D. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61:719–20.PubMedCrossRefGoogle Scholar
  87. 87.
    Thompson AJ. Symptomatic treatment in multiple sclerosis. Curr Opin Neurol. 1998;11:305–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Solaro C, Messmer Uccelli M. Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol. 2011;7:519–27.PubMedCrossRefGoogle Scholar
  89. 89.
    Lienau FS, Füllgraf H, Moser A, Feuerstein TJ. Why do cannabinoids not show consistent effects as analgesic drugs in multiple sclerosis? Eur J Neurol. 2007;14:1162–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2010;29:135–41.Google Scholar
  91. 91.
    Haythornthwaite JA, Benrud-Larsen LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000;16:S101–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Duarte R. In: Kanner R, editor. Pain management secrets, vol. 6. Philadelphia: Hanley & Belfus; 2003.Google Scholar
  93. 93.
    • Saverino A, Solaro C. Pain in individuals with multiple sclerosis, knee prosthesis, and post-herpetic neuralgia: learning from focus group patients' experience. Clin J Pain. 2012;28(4):300–8. Unique, spontaneous descriptors, possibly disease-specific, emerged in various focus groups of subjects with MS and other diseases. All disease groups used descriptors not included in the McGill Pain Questionnaire, underlining the need for assessment measures of pain based on individual perception.PubMedCrossRefGoogle Scholar
  94. 94.
    Vermote R, Ketalaer P, Carlton H. Pain in multiple sclerosis patients: a prospective study using the McGill Pain Questionnaire. Clin Neurol Neurosurg. 1986;88:87–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Claudio Solaro
    • 1
    Email author
  • Erika Trabucco
    • 1
  • Michele Messmer Uccelli
    • 2
  1. 1.Head and Neck Department, Neurology UnitASL 3 GenoveseGenoaItaly
  2. 2.Department of ResearchGenoaItaly

Personalised recommendations